Cytokinesproduction by blood immune cells in patients of different age groups with invasive ductal carcinoma of no special type and lymphatic metastases

The aim of this study was to evaluate production of cytokines by the blood immune cells in patients of different age groups with invasive non-specified type mammary ductal carcinoma, with or without metastases. Production of cytokines by periphery blood immunocompetent cells, either spontaneous and stimulated with polyclonal activators, was assessed in 82 patients with invasive mammary ductal carcinoma. The concentrations of IL-6, IL-8, IL-10, IL-17, IL-18, IL-1p, IL-1ra, TNFa, IFNy, G-CSF, GM-CSF, VEGF и MCP-1 were determined by solid-phase enzyme-linked immunosorbent assay. The patients were divided into 2 age groups: the first group consisted of 48 patients from 45 to 60 years old; the second group consisted of 34 older patients (61 to 75 years old). Metastases in local lymph nodes were documented in twenty patients from the first group and nine patients from the second group. The younger patients (45-60 years old) with metastases in local lymph nodes showed higher polyclonal activation index of IL-4 and IL-1ra production, when compared to the patients without lymphatic metastases. As for the older patients (61 to 75 years old), their polyclonal activation index of IL-6, IL-8, IL-1ra, G-CFS, GM-CSF production was significantly lower in cases of local lymph nodes metastases. The latter was due to higher level of spontaneous production, which suppressed the influence of polyclonal activators. The index of polyclonal activation upon production of cytokines in patients with lymphatic metastases was shown to be significantly higher for the age group of 45 to 60 years than in the age group of 61 to 75 years old. This fact suggested a highly stimulating effect of polyclonal activators in patients younger than 60 years. It was found that correlation between the index of polyclonal activation of cytokine production, and the indexes of ER, PR, HER2/NEU and Ki-67 receptor expression, which are used for the determination of molecular genetic subtype of the tumor, differ significantly for the distinct age groups.

1. Sosnina A.V., Velikaya N.V.,Varaksin N.A., Grishaev M.P., Autenshlyus A.I. The role of cytokines in the pathogenesis of malignant neoplasms. Novosibirsk: Ofset, 2014. 128 p.

2. Cetean S., Cainap C., Constantin A., Cainap S., Gherman A., Oprean L., Hangan A., Oprean R. The importance of the granulocyte-colony stimulating factor in oncology. Clujul Med., 2015, Vol. 88, no. 4, pp. 468-472.

3. Coppe J., Desprez P., Krtolica A., Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol., 2010, Vol. 5, pp. 99-118.

4. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 2005, Vol. 365, no. 1687, p. 717.

5. Gameiro C.M., Romao F., Castelo-Branco C. Menopause and aging: changes in the immune system - a review. Maturitas, 2010, Vol. 67, no. 4, p. 316.

6. Garcla-Tunon I., Ricote M., Ruiz A.A., Fraile B., Paniagua R., Royuela M. Influence of IFN-gamma and its receptors in human breast cancer. BMC Cancer, 2007, Vol. 7, p. 158.

7. Giordano S.B., Gradishar W. Breast cancer: updates and advances in 2016. Curr. Opin. Obstet. Gynecol., 2017, Vol. 29, no. 1, pp. 12-17.

8. Gonzalez H., Hagerling C., Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes and Dev., 2018, Vol. 32, no. 19-20, pp. 1267-1284.

9. Herrera A.C., Panis C., Victorino V.J., Campos F.C., Colado-Simao A.N., Cecchini A.L., Cecchini R. Molecular subtype is determinant on inflammatory status and immunological profile from invasive breast cancer patients. Cancer Immunol. Immunother., 2012, Vol. 61, no. 11, pp. 2193-201.

10. Keunhee O., Ok-Young L., Yeonju P., Myung W.S., Dong-Sup L. IL-1 p induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells. BMC Cancer, 2016, Vol. 16, no. 1, p. 724.

11. Li Z., Jiang J., Wang Z., Zhang J., Xiao M., Wang C., Lu Y., Qin Z. Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis. Cancer Res., 2008, Vol. 68, no. 21, p. 94.

12. Mauer J., Denson J.L., Bruning J.C. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol., 2015, Vol. 36, no. 2, pp. 92-101.

13. Nagini S. Breast cancer: current molecular therapeutic targets and new players. Anticancer Agents Med. Chem., 2017, Vol. 17, no. 2, pp. 152-163.

14. Pfeilschifter J., Kbditz R., Pfoh M., Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr. Rev., 2002, Vol. 23, no. 1, pp. 90-119.

15. Szomolay B., Eubank T.D., Roberts R.D., Marsh C.B., Friedman A. Modeling the inhibition of breast cancer growth by GM-CSF. J. Theor. Biol., 2012, Vol. 303, no. 141 p. 51.

16. Todaro M., Lombardo Y., Francipane M.G., Alea M.P., Cammareri P., Iovino F., Di Stefano A.B., di Bernardo C., Agrusa A., Condorelli G., Walczak H., Stassi G. Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ., 2008, Vol. 4, no. 762, p. 72.

17. Tortorella C., Simone O., Piazzolla G., Stella I., Antonaci S. Age-related impairment of GM-CSF-induced signalling in neutrophils: role of SHP-1 and SOCS proteins. Ageing Res. Rev., 2007, Vol. 6, no. 2, pp. 81-93.

18. Yazdkhasti M., Tourzani Z.M., Roozbeh N., Hasanpour V. Saeieh S.E., Abdi F. The association between diabetes and age at the onset of menopause: a systematic review protocol. Syst. Rev., 2019, Vol. 8, no. 1, p. 80.